Professional Documents
Culture Documents
Jurnal Sistemik
Jurnal Sistemik
Jurnal Sistemik
Case Report
A Rare Case of Melanosis of the Hard Palate Mucosa in
a Patient with Chronic Myeloid Leukemia
Copyright © 2015 Umberto Romeo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the
chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a
good quality of life. Despite its beneficial effects, Imatinib has significant side effects such as mucosal pigmentation. A 72-year-old
female having an Imatinib induced mucosal pigmentation is presented: she has been treated with Imatinib since 2003 and only in
2014 discovered, during a routine dental visit, having a pigmented lesion on her hard palate mucosa. Histopathologically, the lesion
shows the deposition of fine dark brown spherical bodies within the lamina propria and cloaked in between the collagen fibers.
There was no sign of inflammation, hyperplasia, or hemorrhage in the tissue.
Figure 1: Diffuse, blue-grey pigmented lesion of the hard palate Figure 2: Palatal mucosa with a minor salivary gland containing
mucosa of our case. pigment within the lamina propria (HE ×40).
Figure 4: Fine spherical brown particles cloaked in between the Conflict of Interests
collagen fibers in the lamina propria (HE ×400).
The authors declare that there is no conflict of interests
regarding the publication of this paper.
of the hard palate mucosa. The lesion, histopathologically,
showed the presence of fine brown spherical particles within References
the lamina propria, which were both positive for Prussian
[1] C.-C. Li, S. M. Malik, B. F. Blaeser et al., “Mucosal pigmentation
blue and Fontana-Masson stains, indicating the presence
caused by imatinib: report of three cases,” Head and Neck
of hemosiderin and melanin, respectively. There was no Pathology, vol. 6, no. 2, pp. 290–295, 2012.
evidence of malignancy, and both the clinical and histopatho-
[2] A. Kauzman, M. Pavone, N. Blanas, and G. Bradley, “Pigmented
logical presentation confirmed the diagnosis of drug-related lesions of the oral cavity: review, differential diagnosis, and case
melanosis of the mucosa, Imatinib in this case. presentations,” Journal of the Canadian Dental Association, vol.
Imatinib Mesylate works by inhibiting BCR-ABL by 70, no. 10, pp. 682–683, 2004.
binding the ATP site in an “off mode” so that the enzymatic [3] U. Mattsson, S. Halbritter, E. M. Serikoff, L. Christerson, and
activity of the protein is not catalyzed anymore [7, 8]. G. Warfvinge, “Oral pigmentation in the hard palate associated
Dermatological side effects of Imatinib are common such with imatinib mesylate therapy: a report of three cases,” Oral
as rash, superficial edema, Graft Versus Host-like disease, Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and
erythroderma, and lichenoid eruptions. Despite these com- Endodontology, vol. 111, no. 5, pp. e12–e16, 2011.
mon side effects, Gleevec has rarely been reported to produce [4] H. Kantarjian, C. Sawyers, A. Hochhaus et al., “Hematologic
diffuse hyperpigmentation of the palatal mucosa. and cytogenetic responses to imatinib mesylate in chronic
Generally, medication-induced melanosis in the oral myelogenous leukemia,” The New England Journal of Medicine,
mucosa can be attributed to any one of the following vol. 346, no. 9, pp. 645–652, 2002.
mechanisms: pigmented breakdown of drug products, drugs [5] E. C. Besa, B. Buehler, M. Markman, R. A. Sacher, and K.
inducing melanin formation, or drug metabolites chelated Krishnan, Eds., Chronic Myelogenous Leukemia Treatment &
with iron and melanin. Management, Medscape, 2014.
The pathogenesis of oral mucosal pigmentation in [6] J. A. Loudona, H. G. Colemanb, C. M. Allenc, and M. Schifterd,
patients taking Imatinib still remains unclear; it has been sug- “Rare oral manifestation of chronic myelogenous leukemia
gested that Imatinib blocks the binding on the c-kit receptors and its targeted therapy: a case report and literature review,”
(a growth factor receptor found on skin cell, melanocytes, and Universal Journal of Medicine & Dentistry, vol. 1, no. 7, pp. 79–85,
mast cells) and subsequently alters both melanogenesis and 2012.
melanocyte homeostasis [2, 9]. However, pigmented deposi- [7] Novartis Pharmaceuticals Corporation, Gleevec (Imatinib Mesy-
tions in the oral mucosa indicate much different pathologies late) Tablets Prescribing Information, Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA, 2006.
and are challenging to diagnose correctly. Differential diag-
nosis includes physiological pigmentation, amalgam tattoo, [8] Anon, “Drugs of choice for cancer,” Treatment Guidelines from
the Medical Letter, vol. 1, pp. 41–52, 2003.
melanotic macule, smoker’s melanosis, melanocytic nevus,
malignant melanoma, and drug-induced melanosis. [9] Medscape Reference, “Gleevec (imatinib) dosing, indications,
interactions, adverse effects, and more,” 2014, http://reference
The two most common types of melanotic alteration
.medscape.com/drug/gleevec-imatinib-342239#showall.
are physiological pigmentations, which are related to racial
[10] S. B. Woo, Ed., Oral Pathology—A Comprehensive Atlas and
melanosis (mostly diffuse changes on the attached gingiva)
Text, vol. 9, Pigmented Lesions, 2012.
and postinflammation melanosis, as a consequence of a
trauma. [11] A. Yuan and S.-B. Woo, “Adverse drug events in the oral cavity,”
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,
Melanotic macule and melanocytic nevus are rare, but
vol. 119, no. 1, pp. 35–47, 2014.
in 90% of cases they are located in the hard palate mucosa,
which is why they were included in the differential diagnosis.
Pigmented lesions related to systemic diseases were
also considered. Addison’s disease and Peutz-Jeghers syn-
drome could lead to an oral melanosis condition such as